midodrine vasopressorantihypotensive agent raises blood pressure midodrine approved united states food drug administration fda treatment dysautonomia orthostatic hypotension august fda proposed withdrawing approval manufacturer shire plc failed complete required studies medicine reached september fda reversed decision remove midodrine market allowed remain available patients shire plc collected data regarding efficacy safety shire announced september withdrawing completely supplying midodrine leaving several generics supply midodrine indicated treatment symptomatic orthostatic hypotension reduce dizziness faints third limited troublesome goose bumps skin itch gastrointestinal discomfort chills elevated blood pressure lying urinary metaanalysis clinical trials midodrine droxidopa patients low blood pressure standing found midodrine increased standing blood pressure droxidopa midodrine droxidopa increased risk high blood pressure lying small studies also shown midodrine used prevent excessive drops blood pressure people requiring midodrine used complications cirrhosis also used octreotide hepatorenal syndrome proposed mechanism constriction splanchnic vessels dilation renal vasculature studies sufficiently well conducted show clear place midodrine contraindicated patients severe organic heart disease acute kidney disease urinary retention pheochromocytoma thyrotoxicosis midodrine used patients persistent excessive supine headache feeling pressurefullness head vasodilationflushing face scalp tingling confusionthinking abnormality dry mouth nervousnessanxiety midodrine prodrug forms active metabolite desglymidodrine agonist exerts actions via activation alphaadrenergic receptors arteriolar venous vasculature producing increase vascular tone elevation blood pressure desglymidodrine stimulate cardiac betaadrenergic receptors desglymidodrine diffuses poorly across barrier therefore associated effects central nervous system oral administration midodrine rapidly absorbed plasma levels prodrug peak half hour decline halflife approximately minutes metabolite reaches peak blood concentrations hours dose midodrine halflife hours absolute bioavailability midodrine measured desglymidodrine midodrine odorless white crystalline powder soluble water sparingly soluble midodrine contains stereocenter consists two enantiomers making racemate ie mixture r acylation chloroacetyl chloride gives chloroketone halogen converted amine set standard schemes ketone reduced alcohol borohydride acylation amino group last intermediate chloroacetyl chloride affords amide halogen displaced azide resulting product reduced catalytically glycinamide midodrine media related midodrine wikimedia commons httpsenwikipediaorgwikimidodrine